ClinicalTrials.gg
CompletedNCT03378648Updated May 7, 2020

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

A Phase 1/2 interventional study of CHF6366 and Placebo CHF6366 in Asthma and Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
30th of 66
118 · median 97
Started
2017
with 4 others
Phase 1/2
3 of 81
none open now
Registered
51st of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 30th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2017, is one of 3 in phase 1/2, and was the 51st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

CHF6366 is a novel bifunctional compound displaying both muscarinic receptor antagonist and β2-adrenergic receptor agonist properties (MABA), with the potential to deliver optimal bronchodilation after inhalation dosing via two validated mechanisms in one molecule.

The study will consist of three parts:

Part 1 will consit of two cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF 6366

Part 2 will consist of four cohorts of asthmatic subjects to assess the saftey, tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6366

Part 3 will consist of one cohort of COPD patients to asess safety, tolerability of a single dose of CHF6366 in an active and placebo controlled design

03

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1

  • male subjects aged 18-55 years inclusive;
  • healthy subjects based on medical evaluation including medical history,physical examination, laboratory tests and cardiac testing
  • (BMI) between 18.5 and 32.0 kg/m2 extremes inclusive
  • Non- or ex-smokers who smoked \< 5 pack years (pack-years = the number of cigarette packs per day times the number of years) and stopped smoking > 1 year;
  • Good physical and mental status, determined on the basis of the medical history and a general clinical examination;
  • Lung function equal to or more than 80% of predicted normal value and /FVC ratio > 0.70;

Part 2

  • Adult male and female subjects aged 18 to 75 years
  • Clinical diagnosis of mild persistent asthma
  • FEV1 reversibility of ≥ 12% or 200 ml over the baseline value starting within 30 mins after inhalation of 400 micrograms of salbutamol
  • Patients who are otherwise healthy as determined by medical history, physical examination, 12-lead findings

Part 3

  • Male aged between 40 and 75 years
  • Stable patients with a post-bronchodilator 40% ≤ FEV1 \< 80% of the predicted normal value, post-bronchodilator FEV1/FVC \< 0.7 with salbutamol
  • Current smokers and ex-smokers
  • Response to ipratropium bromide defined as an increase in FEV1 of > 7 % starting 30 minutes after inhalation of 80 micrograms ipratropium bromide
  • Response to salbutamol defined an increase in FEV1 of > 7 % starting 15 minutes to 30 min following inhalation of 400 micrograms salbutamol MDI

Exclusion criteria

Exclusion Criteria:

Part1

  • Any abnormabilites and/or uncontrolled diseases
  • Abnormal laboratory values
  • Recent respiratory tract infection
  • to the drug
  • Positive serology results
  • Positive cotinine, alcohol, drug of abuse tests

Part 2

  • Pregnant and/or breast-feeding women
  • Subjects with a medical history or current diagnosis of or any other pulmonary disease other than asthma
  • Subjects who have cardiovascular condition
  • Clinically significant laboratory abnormalities
  • Subject with serum potassium level below the lower limit of the laboratory reference range
  • History of alcohol, substance or drug abuse
  • Hypersensitivity to the drug excipients

Part 3

  • Female patients
  • Current diagnosis of asthma or allergic rhinitis or other atopic disease
  • Recent COPD exacerbations or a lower respiratory tract infection
  • Hypersensitivity to drug excipients;
  • Abuse of substance or drug t or with a positive urine drug screen
  • Unstable concurrent disease
  • Subjects who have cardiovascular condition
  • Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease
  • Patients with serum potassium levels below the lower limit of the laboratory normal range
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    CHF6366 active

    Drug: CHF6366

  • Placebo comparator
    CHF6366

    Drug: Placebo CHF6366

  • Active comparator
    Comparator

    Drug: umeclidinium bromide and vilanterol trifenatate

Interventions

  • DrugCHF6366

    Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject) Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days Drug: CHF6366 (Part 3) Single dose of CHF6366

  • DrugPlacebo CHF6366

    Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects) Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days Drug: Placebo (Part 3) Single dose of placebo matching CHF6366

  • Drugumeclidinium bromide and vilanterol trifenatate

    Drug pages: Umeclidinium bromide · Vilanterol trifenatate

    Part 3 Single dose

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Time frame: Part 1 from Day 1 until day 3, Part 2 from Day 1 until day 8, Part 3 from Day 1 until Day 3 (per each period)

  2. Vital signs

    Systolic, diastolic Blood Pressure

    Time frame: Part 1 from Day 1 until Day 3, Part 2 from Day 1 until day 8, Part 3 from Day 1 until Day 3 (per each period)

  3. Change in Holter ECG parameters

    HR, PR, QRS, QTcF, QT

    Time frame: Part 1 from Day 1 until Day 3, Part 2 from Day 1 until day 8, Part 3 from Day 1 until Day 3 (per each period)

  4. Change in Holter parameters

    Time frame: Part 1 from Day 1 until Day 3, Part 2 from Day 1, until Day 8, Part 3 from Day 1 until Day 3(per each period)

  5. Change in FEV1

    Forced expiratory capacity in the first second

    Time frame: Part 1 drom Day 1 until Day 3, Part 2 from Day 1 until Day 8

  6. Change in Laboratiry parameters

    clinical chemistry, haematology and urinanalysis

    Time frame: Part 1 Day -1 and Day 3, Part 2 Day -2 and Day 8, Part 3 Day -1 and Day 2

  7. Change in serum potassium level

    Time frame: Part 1 Day 1, Part 2 Day 1 and Day 7, Part 3 Day 1

Secondary outcomes

  1. Area under the plasma concentration vs time curve

    Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)

  2. Peak plasma concentration (Cmax)

    maximum plasma concentration of CHF6366

    Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)

  3. Time to reach the maximum plasma concentration (tmax)

    Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)

  4. Elimination half-life (t1/2)

    Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)

  5. Clearance (CL/F)

    Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)

  6. Volume of distribution (Vz/F)

    Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)

  7. Area under the plasma concentration vs time curve during selected dosing interval

    Time frame: Part 2 Day 7

  8. Peak plasma concentration during selected dosing (Cmaxss)

    Time frame: Part 2 Day 7

  9. Value of minimum plasma concentration post dosing at selected dosing interval (Cminss)

    Time frame: Part 2 Day 7

  10. Time of minimum plasma concentration post dosing at selected dosing interval (Tminss)

    Time frame: Part 2 Day 7

  11. Time to reach the maximum plasma concentration at selected dosing interval(tmaxss)

    Time frame: Part 2 Day 7

  12. Clearance at selected dosing interval (CL/Fss)

    Time frame: Part 2 Day 7

  13. Volume of distribution at selected dosing interval (Vz/Fss)

    Time frame: Part 2 Day 7

  14. Accumulation ratio (Rac)

    Time frame: Part 2 Day 7

  15. Steady state concentration (Css)

    Time frame: Part 2 Day 7

  16. Urinary excretion (Ae)

    Time frame: Part 1 from Day 1 until Day 3, Part 2 Day 1 and Day 7, Part 3 from Day 1 until Day 3 (per each period)

  17. fraction excreted (fe)

    Time frame: Part 1 from Day 1 until Day 3, Part 2 Day 1 and Day 7, Part 3 from Day 1 until Day 3 (per each period)

  18. Clearance (CLr)

    Time frame: Part 1 from Day 1 until Day 3, Part 2 Day 1 and Day 7, Part 3 from Day 1 until Day 3 (per each period)

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Apr 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 20, 2017
StartActual
Dec 28, 2017
Primary completionActual
Apr 16, 2019
CompletionActual
Apr 16, 2019
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03378648
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Dec 28, 2017
Primary completion
Apr 16, 2019
Completion
Apr 16, 2019
Last update
May 7, 2020

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion